Study: 18F-FLT helps track patients' response to treatment

10/8/2009 | HealthImaging.com

An Australian study that compared results of baseline PET/CT scans using the 18F-fluorothymidine tracer with routine staging 18F-FDG PET/CT scans found that 18F-FLT allowed for monitoring of changes in the cellular spread of nonsmall-cell lung cancer during chemo-radiotherapy. The findings show that the 18F-FLT tracer could be useful in improving NSCLC treatments based on patients' response.

View Full Article in:

HealthImaging.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX